Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19

Namida Lab

Status: Completed

Conditions: Covid19; SARS-CoV 2 Infection

Treatments: Diagnostic Test: SARS-CoV2 Autoantibody detection

Study type: Observational

Funder types: Industry

Identifiers

NCT04542980

CVDTRS001

Details and patient eligibility

About

This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.

Enrollment: 44 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older Has been tested for SARS-CoV2 and awaiting results Sample collection for SARS-CoV2 testing Tested positive for SARS-CoV2 virus (confirmed by RT-PCR) prior to enrollment

Exclusion criteria

• Under 18 years of age Concurrent eye infection or trauma unrelated to presence of SARS-CoV2 virus. Advanced COVID-19 state what would preclude safe and feasible sample collection.

Trial design

44 participants in 2 patient groups

SARS-CoV2 Positive

Description:

Tear Samples: Tear samples will be collected from 100 patients who have tested positive for the SARS-CoV2 virus. A total of 100 Blood samples will be drawn using standard phlebotomy techniques for venipuncture from patients who have tested positive for the SARS-CoV2 virus.

Treatment:

Diagnostic Test: SARS-CoV2 Autoantibody detection

Control

Description:

Control tear and serum samples will be selected from Namida Lab's own biorepository.